KEGG   DRUG: Carbidopa, levodopa and entacaponeHelp
Entry
D10293            Mixture   Drug                                   

Name
Carbidopa, levodopa and entacapone;
Stalevo (TN)
Product
  Generic
Component
Carbidopa hydrate [DR:D00558], Levodopa [DR:D00059], Entacapone [DR:D00781]
Class
Neuropsychiatric agent
 DG01967  Antiparkinson agent
Remark
Therapeutic category: 1169
ATC code: N04BA03
Product: D10293<JP/US>
Efficacy
Antiparkinsonian
  Disease
Parkinson disease [DS:H00057]
Comment
Entacapone is an inhibitor of COMT and CYP2C9.
Interaction
CYP inhibition: CYP2C9 [HSA:1559]
Enzyme inhibition: COMT [HSA:1312]
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 N NERVOUS SYSTEM
  N04 ANTI-PARKINSON DRUGS
   N04B DOPAMINERGIC AGENTS
    N04BA Dopa and dopa derivatives
     N04BA03 Levodopa, decarboxylase inhibitor and COMT inhibitor
      D10293  Carbidopa, levodopa and entacapone <JP/US>
USP drug classification [BR:br08302]
 Antiparkinson Agents
  Antiparkinson Agents, Other
   Carbidopa/ Levodopa/ Entacapone
    D10293  Carbidopa, levodopa and entacapone
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   116  Antiparkinsonian agents
    1169  Others
     D10293  Carbidopa, levodopa and entacapone
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10293
BRITE hierarchy
Other DBs
PubChem: 163312324
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system